On January 16, 2020, the European Patent Office (EPO) Board of Appeal dismissed the appeal for the CRISPR patent, which covers gene-editing technology, upholding the EPO’s Opposition Division’s decision to revoke the patent for lack of novelty. Law360 quoted Finnegan’s European IP Blog in its article: “The key message to take away is that ensuring priority is claimed validly is crucial. To avoid any issues at the EPO, applicants must make sure that they have the right to claim priority at the application filing date."
Read the full article here.